GlaxoSmithKline Plc has raised its stake to 19% from about 12% in Theravance Inc, a US biopharmaceutical company with whom it has a collaboration in respiratory medicines. The transaction is valued at $129 million. ---Subscribe to MedNous to access this article--- Company News Finance, Grants, Deals
